Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/68648
Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
The development of new immunosuppressants for renal transplantation is aimed not only at improving short-term outcomes, but also at achieving better safety, cardiovascular, and metabolic profiles and at decreasing nephrotoxicity. Belatacept is a fusion protein that inhibits T cell activation by binding to CD80 and CD86 antigens. Clinical trials, particularly the BENEFIT and BENEFIT-EXT studies, have shown that belatacept preserves function and structure in renal grafts. The effects of belatacept provide long-term, sustained results, and the safety and efficacy of this drug have been demonstrated in cases of renal transplantation from expanded criteria donors. Compared to calcineurin inhibitors, belatacept is associated with a lower incidence of chronic allograft nephropathy and a more favourable cardiovascular and metabolic profile.
Matèries (anglès)
Citació
Citació
BESTARD MATAMOROS, Oriol, CAMPISTOL PLANA, Josep m., MORALES, José m., SÁNCHEZ-FRUCTUOSO, A., CABELLO, Mercedes, CABELLO, Virginia, PALLARDÓ, Luis m., GRINYÓ BOIRA, Josep m.. Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk. _Nefrología_. 2012. Vol. 32, núm. 3, pàgs. 374-384. [consulta: 23 de gener de 2026]. ISSN: 0211-6995. [Disponible a: https://hdl.handle.net/2445/68648]